---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-091826"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:06:34.804533+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Acadia Q2 total revenue up 46% to $242M; net income $33.4M vs $1.1M last year

## Summary
- NUPLAZID net sales $157.4M (+11% YoY); DAYBUE net sales $84.6M (vs $23.2M YoY).
- Net income $33.4M ($0.20 EPS) vs $1.1M ($0.01 EPS) in Q2 2023.
- NUPLAZID FY guidance raised to $590-610M; DAYBUE lowered to $340-370M.
- Total revenue FY guidance revised to $930-980M (from $930M-$1.01B).
- Cash and investments $500.9M at June 30, 2024, up from $438.9M at Dec 31, 2023.

## SEC filing metadata
- accession: 0000950170-24-091826
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000095017024091826/0000950170-24-091826-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000095017024091826/acad-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-091826
- JSON: https://secwatch.observer/filing/0000950170-24-091826.json
- Plain text: https://secwatch.observer/filing/0000950170-24-091826.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.